ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,040,907 | $5,129,173 | $2,573,993 | $3,745,907 |
| - Cash | $319,589 | $188,657 | $114,846 | $147,435 |
| + Debt | $51,995 | $57,205 | $62,000 | $56,126 |
| Enterprise Value | $2,773,313 | $4,997,721 | $2,521,147 | $3,654,598 |
| Revenue | $957,797 | $726,437 | $517,235 | $484,145 |
| % Growth | 31.8% | 40.4% | 6.8% | – |
| Gross Profit | $875,956 | $680,706 | $507,069 | $465,004 |
| % Margin | 91.5% | 93.7% | 98% | 96% |
| EBITDA | $100,162 | -$67,827 | -$221,570 | -$167,095 |
| % Margin | 10.5% | -9.3% | -42.8% | -34.5% |
| Net Income | $226,451 | -$61,286 | -$215,975 | -$167,870 |
| % Margin | 23.6% | -8.4% | -41.8% | -34.7% |
| EPS Diluted | 1.36 | -0.37 | -1.34 | -1.05 |
| % Growth | 467.6% | 72.4% | -27.6% | – |
| Operating Cash Flow | $157,719 | $16,702 | -$114,035 | -$125,660 |
| Capital Expenditures | -$523 | -$40,050 | $0 | -$1,122 |
| Free Cash Flow | $157,196 | -$23,348 | -$114,035 | -$126,782 |